Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  MediciNova, Inc.    MNOV

MEDICINOVA, INC.

(MNOV)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/11/2019 | 07:01pm EDT

LA JOLLA, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 10:30 am at the Sofitel Hotel in New York City.  Management will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative cervical myelopathy (DCM), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin). For more information on MediciNova, Inc., please visit www.medicinova.com.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2018 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

INVESTOR CONTACT:
Geoff O'Brien
Vice President
MediciNova, Inc.
info@medicinova.com

Primary Logo


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDICINOVA, INC.
09/11MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in..
GL
08/29MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New Y..
GL
08/23MEDICINOVA : Form of prospectus disclosing information, facts, events covered in..
PU
08/23MEDICINOVA INC : Entry into a Material Definitive Agreement, Termination of a Ma..
AQ
08/23MEDICINOVA : Effect
PU
08/09MEDICINOVA : Simplified registration form
PU
07/30MediciNova Announces MN-001 Research Collaboration with the National Cerebral..
GL
07/29MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentatio..
GL
07/26MEDICINOVA INC : Regulation FD Disclosure (form 8-K)
AQ
07/25MEDICINOVA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -22,8 M
Net income 2019 -22,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -16,6x
P/E ratio 2020 -13,4x
Capi. / Sales2019 infx
Capi. / Sales2020 infx
Capitalization 359 M
Chart MEDICINOVA, INC.
Duration : Period :
MediciNova, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDICINOVA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 20,67  $
Last Close Price 8,28  $
Spread / Highest target 166%
Spread / Average Target 150%
Spread / Lowest Target 117%
EPS Revisions
Managers
NameTitle
Yuichi Iwaki President, Chief Executive Officer & Director
Jeff Himawan Chairman
Carla Reyes Chief Financial Officer
Kazuko Matsuda Chief Medical Officer
Yutaka Kobayashi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDICINOVA, INC.1.35%359
GILEAD SCIENCES5.07%83 231
VERTEX PHARMACEUTICALS5.32%44 858
REGENERON PHARMACEUTICALS-23.68%31 192
GENMAB27.73%13 383
NEUROCRINE BIOSCIENCES, INC.41.60%9 261